Hideaki Yashima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hideaki Yashima has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Koujirou Yamamoto
Department of Clinical Pharmacology and Therapeutics, Gunma University Graduate School of Medicine, Maebashi, Japan
4 shared publications- Takuya Araki
Department of Clinical Pharmacology and Therapeutics, Gunma University Graduate School of Medicine, Maebashi, Japan
4 shared publications - Jun Morita
Department of Urology, Showa Medical University Hospital, Tokyo, Japan
2 shared publications - Mari Kogo
Division of Pharmacotherapeutics, Department of Clinical Pharmacy, Showa Medical University School of Pharmacy, Tokyo, Japan
2 shared publications - Masayuki Ohbayashi
Division of Pharmacotherapeutics, Department of Clinical Pharmacy, Showa Medical University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan
2 shared publications - Miki Takenaka Sato
Division of Pharmacotherapeutics, Department of Clinical Pharmacy, Showa Medical University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan
2 shared publications
Latest Publications
- 21 January 2026
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 96 (1) , 12
Plasma concentrations of doxorubicin and cyclophosphamide during anthracycline-based chemotherapy in a pregnant breast cancer patient: evaluation of gestational changes
Purpose Anthracycline-based chemotherapy with doxorubicin plus cyclophosphamide (AC) is commonly used for breast cancer during the second and third trimesters of pregnancy, yet pharmacokinetic data for these drugs in pregnant patients are limited. This case report evaluates changes in the plasma concentrations of doxorubicin and cyclophosphamide during pregnancy in a breast cancer patient undergoing AC to clarify the influence of gestation on drug pharmacokinetics. Methods A 39-year-old woman with stage IIA breast cancer diagnosed at 16 weeks of gestation received four cycles of AC, with doses based on her pre-pregnancy body surface area. Plasma concentrations of doxorubicin and cyclophosphamide were measured by LC–MS/MS 24 h after administration during the first and third cycles. Results Doxorubicin concentrations were 5.5 and 8.2 ng/mL in the first and third cycles, respectively, which were lower than reported in non-pregnant patients. Cyclophosphamide concentrations were respectively 1.3 and 1.1 µg/mL, which were comparable to non-pregnant levels. No serious maternal or fetal adverse events were observed, and plasma concentrations remained stable over time. Conclusion Doxorubicin concentrations during pregnancy were 30%–60% lower than those reported in non-pregnant patients. We did not observe a gestational decline in doxorubicin concentrations between the two sampling points in this patient, likely due to gestational changes in factors that can influence pharmacokinetic parameters (e.g., persistent P-glycoprotein upregulation). Cyclophosphamide pharmacokinetics remained unchanged. Although further studies are needed to confirm the optimal dosing and safety, these findings suggest that AC with pre-pregnancy body surface area–based dosing may be feasible in pregnant patients.
- 21 January 2026
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 96 (1) , 12
Plasma concentrations of doxorubicin and cyclophosphamide during anthracycline-based chemotherapy in a pregnant breast cancer patient: evaluation of gestational changes
Purpose Anthracycline-based chemotherapy with doxorubicin plus cyclophosphamide (AC) is commonly used for breast cancer during the second and third trimesters of pregnancy, yet pharmacokinetic data for these drugs in pregnant patients are limited. This case report evaluates changes in the plasma concentrations of doxorubicin and cyclophosphamide during pregnancy in a breast cancer patient undergoing AC to clarify the influence of gestation on drug pharmacokinetics. Methods A 39-year-old woman with stage IIA breast cancer diagnosed at 16 weeks of gestation received four cycles of AC, with doses based on her pre-pregnancy body surface area. Plasma concentrations of doxorubicin and cyclophosphamide were measured by LC–MS/MS 24 h after administration during the first and third cycles. Results Doxorubicin concentrations were 5.5 and 8.2 ng/mL in the first and third cycles, respectively, which were lower than reported in non-pregnant patients. Cyclophosphamide concentrations were respectively 1.3 and 1.1 µg/mL, which were comparable to non-pregnant levels. No serious maternal or fetal adverse events were observed, and plasma concentrations remained stable over time. Conclusion Doxorubicin concentrations during pregnancy were 30%–60% lower than those reported in non-pregnant patients. We did not observe a gestational decline in doxorubicin concentrations between the two sampling points in this patient, likely due to gestational changes in factors that can influence pharmacokinetic parameters (e.g., persistent P-glycoprotein upregulation). Cyclophosphamide pharmacokinetics remained unchanged. Although further studies are needed to confirm the optimal dosing and safety, these findings suggest that AC with pre-pregnancy body surface area–based dosing may be feasible in pregnant patients.
- Open Access
- 9 November 2025
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 269, 117242
Development of an LC-MS/MS method for the quantification of sunitinib and its metabolites in human nail and skin
- 9 November 2025
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 269, 117242
Open AccessDevelopment of an LC-MS/MS method for the quantification of sunitinib and its metabolites in human nail and skin
- 17 September 2025
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 95 (1) , 1-4
Effect of plasma exchange on tirabrutinib plasma concentration in a patient with lymphoplasmacytic lymphoma: A case report
Purpose Tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, is used to treat lymphoplasmacytic lymphoma (LPL). A hallmark complication of LPL is hyperviscosity syndrome (HVS), caused by markedly elevated serum IgM levels. Plasma exchange (PE) is a standard treatment for HVS but may also remove circulating drugs, particularly those with high protein binding, potentially reducing drug exposure and efficacy. Evaluating the impact of PE on the pharmacokinetics of drugs used to treat LPL is important for optimal treatment. Methods We report the case of a 63-year-old man with LPL who presented with acute headache and was diagnosed with HVS. Tirabrutinib (480 mg, once daily) was initiated, and PE was performed the next day because of persistent IgM elevation. To assess the impact of PE on tirabrutinib plasma concentrations, blood samples were collected approximately 3 h prior to PE (C15), immediately before PE (C18), and immediately after PE (C20). Results The concentrations at C15, C18 and C20 were 33.3, 16.9, and 11.4 ng/mL, respectively. The elimination rate constant (ke) was calculated as 0.226 h⁻¹ before PE and 0.197 h⁻¹ during PE. Based on the pre-PE ke, the predicted post-PE concentration (C20) assuming no PE was approximately 10.6 ng/mL, slightly lower than the observed value. Conclusion PE appeared to have minimal impact on the tirabrutinib plasma concentration, likely due to its large volume of distribution. Although further cases are needed, this case supports the feasibility of concomitant PE during tirabrutinib therapy without significant compromise of drug efficacy.
- 17 September 2025
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 95 (1) , 1-4
Effect of plasma exchange on tirabrutinib plasma concentration in a patient with lymphoplasmacytic lymphoma: A case report
Purpose Tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, is used to treat lymphoplasmacytic lymphoma (LPL). A hallmark complication of LPL is hyperviscosity syndrome (HVS), caused by markedly elevated serum IgM levels. Plasma exchange (PE) is a standard treatment for HVS but may also remove circulating drugs, particularly those with high protein binding, potentially reducing drug exposure and efficacy. Evaluating the impact of PE on the pharmacokinetics of drugs used to treat LPL is important for optimal treatment. Methods We report the case of a 63-year-old man with LPL who presented with acute headache and was diagnosed with HVS. Tirabrutinib (480 mg, once daily) was initiated, and PE was performed the next day because of persistent IgM elevation. To assess the impact of PE on tirabrutinib plasma concentrations, blood samples were collected approximately 3 h prior to PE (C15), immediately before PE (C18), and immediately after PE (C20). Results The concentrations at C15, C18 and C20 were 33.3, 16.9, and 11.4 ng/mL, respectively. The elimination rate constant (ke) was calculated as 0.226 h⁻¹ before PE and 0.197 h⁻¹ during PE. Based on the pre-PE ke, the predicted post-PE concentration (C20) assuming no PE was approximately 10.6 ng/mL, slightly lower than the observed value. Conclusion PE appeared to have minimal impact on the tirabrutinib plasma concentration, likely due to its large volume of distribution. Although further cases are needed, this case supports the feasibility of concomitant PE during tirabrutinib therapy without significant compromise of drug efficacy.
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 2025 (1)
Impact of Different Diuretic Protocols on the Prevention of Renal Impairment and Extravasation Incidences During Short Hydration in Cisplatin Administration
The short hydration method using magnesium and diuretics has been widely adopted to prevent cisplatin‐induced nephrotoxicity. Both mannitol and furosemide are commonly used as diuretics in this approach, but there is no clear consensus on the benefits or risks of combining the two. Mannitol is associated with a higher risk of vascular problems, such as extravascular leakage and vasculitis, owing to its high osmolality. In this study, we investigated the risk of vascular problems and cisplatin‐induced nephrotoxicity in patients who underwent short hydration with both mannitol and furosemide and in those who underwent short hydration with furosemide alone during the administration of cisplatin. Propensity score matching was performed to control for background characteristics, and logistic regression analysis was conducted to identify risk factors. The use of both mannitol and furosemide was significantly associated with a higher risk of extravasation (odds ratio [OR] = 8.29) and vascular events (OR = 12.58) compared with the use of furosemide alone. In contrast, the degree of renal function decline and incidence of grade ≥ 2 nephrotoxicity did not significantly differ between the groups. These findings suggest that adding mannitol to furosemide does not provide an additional benefit in preventing cisplatin‐induced nephrotoxicity but may increase the risk of vascular adverse events. Therefore, as a general rule, furosemide alone is recommended as the diuretic in the short hydration method to prevent cisplatin‐induced nephrotoxicity as well as extravascular leakage and vasculitis.
- 1 January 2025
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 2025 (1)
Open AccessImpact of Different Diuretic Protocols on the Prevention of Renal Impairment and Extravasation Incidences During Short Hydration in Cisplatin Administration
The short hydration method using magnesium and diuretics has been widely adopted to prevent cisplatin‐induced nephrotoxicity. Both mannitol and furosemide are commonly used as diuretics in this approach, but there is no clear consensus on the benefits or risks of combining the two. Mannitol is associated with a higher risk of vascular problems, such as extravascular leakage and vasculitis, owing to its high osmolality. In this study, we investigated the risk of vascular problems and cisplatin‐induced nephrotoxicity in patients who underwent short hydration with both mannitol and furosemide and in those who underwent short hydration with furosemide alone during the administration of cisplatin. Propensity score matching was performed to control for background characteristics, and logistic regression analysis was conducted to identify risk factors. The use of both mannitol and furosemide was significantly associated with a higher risk of extravasation (odds ratio [OR] = 8.29) and vascular events (OR = 12.58) compared with the use of furosemide alone. In contrast, the degree of renal function decline and incidence of grade ≥ 2 nephrotoxicity did not significantly differ between the groups. These findings suggest that adding mannitol to furosemide does not provide an additional benefit in preventing cisplatin‐induced nephrotoxicity but may increase the risk of vascular adverse events. Therefore, as a general rule, furosemide alone is recommended as the diuretic in the short hydration method to prevent cisplatin‐induced nephrotoxicity as well as extravascular leakage and vasculitis.
- Open Access
- 26 December 2024
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 95 (1) , 1-10
Variations in serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment
Purpose The blood concentrations of some tyrosine kinase inhibitors are known to decrease with long-term administration. We evaluated the variability in the serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment. Methods This study prospectively recruited patients who received sunitinib for metastatic renal cell carcinoma at the Showa University Hospital between March 2020 and January 2022. Bivariate correlations between the serum concentration/dose (C/D) ratios of sunitinib and its metabolites (i.e., N-desethyl sunitinib and sunitinib N-oxide) and treatment duration were evaluated using Pearson’s correlation coefficient. Results Seven patients were enrolled, and 79 blood samples were collected. Among six patients who received sunitinib for > 1 year, three showed a decreasing trend in the C/D ratio of sunitinib (Pt1: r = -0.608, p = 0.047; Pt2: r = -0.555, p = 0.077; Pt6: r = -0.590, p = 0.073). In these patients, the median annual decrease in the C/D ratio of sunitinib was 55.8% (26.5–63.2%). Additionally, two of the three patients also showed a decrease in the C/D ratio of N-desethyl sunitinib. The ratio of N-desethyl sunitinib/sunitinib concentration at baseline and the end of follow-up was similar between the C/D-decreased and C/D-non-decreased groups. Conclusion This study showed that the C/D ratio of sunitinib decreased by half over time in half of the patients who received long-term sunitinib treatment despite continuing the same dose. Therefore, serum concentrations of sunitinib and its metabolites should be monitored periodically in patients receiving long-term treatment to prevent decrease in serum sunitinib concentrations.
- 26 December 2024
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 95 (1) , 1-10
Open AccessVariations in serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment
Purpose The blood concentrations of some tyrosine kinase inhibitors are known to decrease with long-term administration. We evaluated the variability in the serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment. Methods This study prospectively recruited patients who received sunitinib for metastatic renal cell carcinoma at the Showa University Hospital between March 2020 and January 2022. Bivariate correlations between the serum concentration/dose (C/D) ratios of sunitinib and its metabolites (i.e., N-desethyl sunitinib and sunitinib N-oxide) and treatment duration were evaluated using Pearson’s correlation coefficient. Results Seven patients were enrolled, and 79 blood samples were collected. Among six patients who received sunitinib for > 1 year, three showed a decreasing trend in the C/D ratio of sunitinib (Pt1: r = -0.608, p = 0.047; Pt2: r = -0.555, p = 0.077; Pt6: r = -0.590, p = 0.073). In these patients, the median annual decrease in the C/D ratio of sunitinib was 55.8% (26.5–63.2%). Additionally, two of the three patients also showed a decrease in the C/D ratio of N-desethyl sunitinib. The ratio of N-desethyl sunitinib/sunitinib concentration at baseline and the end of follow-up was similar between the C/D-decreased and C/D-non-decreased groups. Conclusion This study showed that the C/D ratio of sunitinib decreased by half over time in half of the patients who received long-term sunitinib treatment despite continuing the same dose. Therefore, serum concentrations of sunitinib and its metabolites should be monitored periodically in patients receiving long-term treatment to prevent decrease in serum sunitinib concentrations.